Toltrazuril

As a special triazine anticoccidial drug, toltrazuril exerts a killing effect on coccidia at all developmental stages including schizonts, gametophytes and sporozoites by interfering with the synthesis of ribonucleic acid and protein in coccidial cells and blocking mitochondrial respiratory function, without obvious cross-resistance. Clinically, it is mainly used for the prevention and treatment of various Eimeria coccidiosis in chickens such as Eimeria tenella, Eimeria acervulina and Eimeria necatrix, as well as coccidial infections in livestock and poultry such as rabbits and pigs. It is one of the core drugs used in large-scale farming to control the outbreak of coccidiosis and reduce the mortality rate of livestock and poultry and farming losses.

The global market size of toltrazuril was approximately USD 210 million in 2023, with a compound annual growth rate maintained at around 4.7%. The growth is mainly driven by the expansion of epidemic prevention demand in emerging farming markets such as South America and Southeast Asia. In terms of the domestic market, with the advancement of the action to reduce the use of veterinary antibacterial drugs, the demand for low-toxicity and high-efficiency anticoccidial active pharmaceutical ingredients continues to rise. In 2023, the domestic annual output of toltrazuril exceeded 800 tons, of which approximately 65% was used for export. Domestic manufacturers are concentrated in Shandong and Jiangsu, with leading enterprises accounting for more than 40% of the total production capacity, and the centralized procurement price has dropped by approximately 22% cumulatively compared with 2020.

The original research enterprise of toltrazuril is Bayer AG of Germany, with the original brand name "Baycox". The core compound patent expired in Europe and the United States in 2004, and the compound patent in China expired in 2003. The main dosage forms approved for the original product include 2.5% oral solution and 5% suspension, with specifications covering 100ml, 1L, etc. It has been included in the FDA Reference Listed Drug Catalog, and is also a variety included in China's *Quality Standards for Veterinary Chemical Drugs*. Up to now, 13 domestic enterprises have obtained CDE registration numbers (status A) for toltrazuril active pharmaceutical ingredients, and a total of 27 toltrazuril preparation products including the original research product have been approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for toltrazuril, most of which are available in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can fully meet the needs for impurity reference standards throughout the whole process including active pharmaceutical ingredient R&D, quality research, production inspection, etc.